Recombinant Type II Humanized Collagen With High Bioadhesion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing collagen for cartilage repair, particularly type II collagen, face challenges such as immunogenicity from animal-origin sources, complex impurity removal processes, and unsatisfactory efficacy, leading to slow regeneration and the need for costly and risky artificial joint replacements.
Innovation Solution
A recombinant type II humanized collagen is developed using synthetic biology and structural biology to screen functional regions with specific amino acid sequences, ensuring high expression, easy purification, and stability, allowing direct injection into the human body without immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If animal-origin collagen is used for cartilage repair, then cartilage repair function is provided, but immunogenicity occurs causing immune rejection
Solution Approach 1:
The patent creates a recombinant humanized type II collagen that copies the structure and function of natural human type II collagen. By using human collagen gene sequences expressed in a recombinant system, the product is identical to human native collagen, thereby eliminating immunogenicity while maintaining cartilage repair functionality.
2Quantity of substance
If traditional acid, alkali, and enzymatic hydrolysis methods are used to extract collagen, then collagen derivatives are obtained, but the triple helix structure is lost and biological activity is destroyed
Solution Approach 1:
The patent replaces harsh chemical extraction methods (acid, alkali, enzymatic hydrolysis) with a biological recombinant expression system. The collagen is produced through cellular biosynthesis pathways that naturally maintain the triple helix structure, eliminating the need for destructive chemical processing while preserving biological activity.
3Quantity of substance
If animal cartilage extraction methods are used, then collagen is obtained, but impurity removal processes are complicated and product purity is low
Solution Approach 1:
The patent uses recombinant DNA technology to produce human type II collagen in a controlled expression system. This approach creates a pure product from the start, as the recombinant system only produces the target collagen protein without the complex impurity profile of animal cartilage extracts, greatly simplifying purification processes.
4Reliability
If current treatment methods with low protein utilization rate are used, then cartilage regeneration occurs slowly, but treatment time is extended and efficiency is reduced
Solution Approach 1:
The patent changes the key parameter of collagen bioavailability by using recombinant humanized type II collagen with optimized structure and purity. This form of collagen has higher protein utilization rate compared to traditional treatments, accelerating cartilage regeneration and reducing treatment time while improving therapeutic efficacy.
Data Source
AI summary
Provided is collagen and uses thereof. Collagen includes an N-terminal sequence and a C-terminal sequence, wherein the N-terminal sequence includes one or more repeating units, and the repeating unit includes an amino acid sequence shown in SEQ ID NO. 15. The recombinant type II humanized collagen prepared by the present invention has high activity in promoting cell adhesion, does not produce an immune response when applied to the human body, can be obtained on a large scale, and is expected to be widely used in the field of cartilage repair.